Depotech(depo) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo)

DEPO 7.300

+1.7%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (647)	12/22/1997 3:08:00 PM
From: Czechsinthemail	of 887

mz, I'm still not sure that the toxicity comparison will be fatal for DepoCyt. Michael King suggested that the adverse comparison might reflect more the increased treatment exposure and the insufficient study or consideration of the ameliorating effects that steroids could have in reducing the arachnoiditis problems. The efficacy data, though considered statistically insignificant, remained suggestive of improvement using DepoCyt compared with the control. If more data can prove the benefit and establish that steroid use can control the side effects, DepoCyt may still have some legs. At this point, I think all the negatives are in. That suggests more potential for rebound than further drops in price. With a presumably stronger study for leukemia and lymphoma in the works, I think DEPO price should begin to climb on the prospects. We'll see. Baird

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next